ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 18552176

Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Dutt A and 24 others. Proc Natl Acad Sci U S A, 2008. Cited by 303 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Papers, record 18552176. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18552176

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Drug-sensitive FGFR2 mutations in endometrial carcinoma.
PubMed
Journal
Proc Natl Acad Sci U S A
PubMed
Year
2008
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
303
iCite
Relative citation ratio, by iCite
6
iCite
Revised in PubMed
2021-10-20
PubMed

Authors25

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dutt AAmit
2Salvesen HBHelga B
3Chen THTzu-Hsiu
4Ramos AHAlex H
5Onofrio RCRobert C
6Hatton CCharlie
7Nicoletti RRichard
8Winckler WWendy
9Grewal RRupinder
10Hanna MMegan

1 to 10 of 25Source PubMed

See all 25 authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
Endometrial NeoplasmsMajor topic
MutationMajor topic
Receptor, Fibroblast Growth Factor, Type 2Major topic
Animals
Cell Line, Tumor
Cell Proliferation
Cell Survival
Female
Mice
NIH 3T3 Cells
Transfection

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
U24 CA126546NCI NIH HHSUnited StatesU24CA126546PubMed and NIH

Source NIH RePORTER

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00598845Molecular Markers in Treatment in Endometrial CancerBackgroundClinicalTrials.gov
NCT07811232A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersBackgroundClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117,115,056Automating resequencing-based detection of insertion-deletion polymorphisms.Nat Genet2006https://conductscience.org/library/papers/17115056PubMed
217,487,277Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.PLoS One2007https://conductscience.org/library/papers/17487277PubMed
315,329,413EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci U S A2004https://conductscience.org/library/papers/15329413PubMed
414,499,350A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis.Bone2003https://conductscience.org/library/papers/14499350PubMed
59,700,203Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.Hum Mol Genet1998https://conductscience.org/library/papers/9700203PubMed
69,774,334Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.EMBO J1998https://conductscience.org/library/papers/9774334PubMed
78,663,044Receptor specificity of the fibroblast growth factor family.J Biol Chem1996https://conductscience.org/library/papers/8663044PubMed
815,863,034Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations.Cytokine Growth Factor Rev2005https://conductscience.org/library/papers/15863034PubMed
911,248,153Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med2001https://conductscience.org/library/papers/11248153PubMed
1012,181,401Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med2002https://conductscience.org/library/papers/12181401PubMed

1 to 10 of 41

See all 41 references

Cited by180

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 303 citations.

PMIDTitleJournalYearIn PapersSource
42,809,705Auranofin Potentiates Cisplatin Response in the Setting of Context-Dependent NOTCH-Associated Signaling States in Endometrial Cancer.Cancer Res Commun2026https://conductscience.org/library/papers/42809705PubMed
42,633,326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326PubMed
42,082,645Long-term survival without high cancer risk in a cohort of 24 patients with Apert syndrome.Eur J Hum Genet2026https://conductscience.org/library/papers/42082645PubMed
41,361,008Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.Nat Genet2026https://conductscience.org/library/papers/41361008PubMed
41,226,813FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities.Int J Mol Sci2025https://conductscience.org/library/papers/41226813PubMed
40,843,798Pilomatricoma in Syndromic Contexts: A Literature Review and a Report of a Case in Apert Syndrome.Dermatopathology (Basel)2025https://conductscience.org/library/papers/40843798PubMed
40,683,601Nanocarrier drug delivery systems for gynecological cancer therapeutics.J Control Release2025https://conductscience.org/library/papers/40683601PubMed
40,338,217Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report.Oncologist2025https://conductscience.org/library/papers/40338217PubMed
39,941,769Brain Metastasis in Endometrial Cancer: A Systematic Review.Cancers (Basel)2025https://conductscience.org/library/papers/39941769PubMed
39,675,505Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.Am J Pathol2025https://conductscience.org/library/papers/39675505PubMed

1 to 10 of 180

See all 180 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/18552176

GET https://conductscience.org/api/papers/v1/18552176/authors?page=2

API referenceFor AI assistants